Telendo announces a pre-seed capital increase, marking a milestone in the development of the MedTech start-up. On this occasion, SATT Sayens, Factory 319 and Patrick Bérard are acquiring a stake in Telendo in order to support the company in accelerating its technological, industrial and commercial development.
This fundraising confirms the appeal of the Telendo project. Founded to transform the use of endoscopic data through an advanced digital platform, Telendo aims to offer new tools to aid diagnosis and medical documentation, based on digital organ reconstruction, artificial intelligence and automated structuring of clinical video streams.
Romain Liège, Chairman of SATT Sayens, states:
« Telendo is a promising innovative start-up, founded on a solid and recognised scientific and technological base, supported by teams from the University of Lorraine and the CNRS within the CRAN laboratory led by Professor Christian Daul. By investing in its capital, we are affirming our confidence in its vision and ambitions. This partnership will support its development, accelerate its industrialisation and stimulate its commercial growth. We also welcome the decisive role played by regional innovation stakeholders — the Incubateur Lorrain, the ERDF, the Grand Est Region and Bpifrance — who made the creation of Telendo possible. »
Hédi Miachau, Co-founder and Chief Executive Officer of Factory 319 Group:
« This investment demonstrates our confidence in Telendo's team and unique technology, which can convert imaging data streams into usable reconstructions to improve visualisation, traceability and medical decision support. Our investment is fully in line with our mission: to nurture healthcare champions by combining technological excellence with measurable impacts on our healthcare system. »
Carsten Müller, co-founder and CEO of Telendo, explains: Telendo, précise :
« I am very pleased to have co-founded Telendo and to be leading this MedTech company alongside a team of leading experts, within a dynamic regional ecosystem that places health and digital innovation at the heart of its priorities. I have great ambitions for Telendo, and I will be drawing fully on my entrepreneurial and industrial experience in healthcare innovation to achieve them. We can also count on the strategic support of SATT Sayens. The next steps—full development of our platform, clinical validation and industrial expansion—will be decisive, but I am confident: we have built a strong and complementary team, ready to take on these challenges and transform the practice of endoscopy. »
About SATT Sayens
As a Technology Transfer Acceleration Company, SATT Sayens brings promising scientific results to the fore, transforming them into innovations that meet the needs of businesses and the market, driving growth and job creation. Working alongside researchers and businesses to make science the future of innovation, Sayens has access to the skills of 6,500 researchers and 4,000 doctoral students from 140 public research laboratories across the Grand Est (Lorraine and South Champagne Ardenne-Troyes) and Bourgogne-Franche-Comté regions.
By the end of 2024: 1,083 projects identified, €42 million invested in 197 projects, 45 deep tech start-ups created, 458 intellectual property assets, a portfolio of 342 protected and de-risked technologies.
About Factory 319
Factory 319 is helping to shape the future of healthcare by combining innovation, expertise and entrepreneurship. As a start-up studio specialising in the digital health sector, Factory 319 co-creates and develops companies that respond to complex healthcare challenges and meet the expectations of various stakeholders in the sector.
With a proven methodology and a collaborative approach, we support entrepreneurs, researchers, and investors at every stage of a project: from ideation to deployment, from product validation to the acceleration phase.
